Clay Siegall’s Hope for Cancer Patients

Clay Siegall is the President, CEO and Chairman of Board at the Seattle Genetics; a company that is involved in research, innovation, and development of drugs. He is also a co-founder of the company and has been in operation since 1998. The firm has developed Antibody drug conjugates, which was approved by FDA in 2011. Seattle Genetics is also working to develop ADC that can be used in cancer treatment. ADC technology has earned the company more than three hundred and twenty-five million dollars up to date. The organization is targeting a variety of cancer and autoimmune indications by developing a portfolio of preclinical and clinical products.

Seattle Genetics aim is to improve lives for cancer patients through innovation of antibody-based therapies. Their team of innovative and dedicated scientists has a passion to helping the sick and that motivate them to work tirelessly to make innovations. The firm has entered into some collaborations including with CuraGen, Bayer, Progenics, Genentech and MedImmune; its collaboration with Genentech for SGN-40 was valued at eight hundred and sixty million dollars.

Dr. Clay Siegall attended the University of Maryland and earned a Bachelor of Science in Zoology and Ph.D. in genetics at The George Washington University. In 2013, he was awarded by the University of Maryland as the Alumnus of the year for Computer, Math and Natural Science and Entrepreneur of the year in 2012 by Pacific Northwest Ernst & Young. As at 2015, Dr. Siegall was earning 6,871,245 dollars; he served as the Executive Vice President before he became the President in 2000.

Presently, aside from being the president at Seattle Genetics, Clay Siegall is also the Director of the Board at Ultragenyx Pharmaceutical, Alder Biopharmaceuticals Inc., and Mirna Therapeutics. Before co-founding Seattle Genetics, he worked with National Cancer Institute, National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. Dr. Siegall has more than twenty years of experience in cancer research and drug development and has a passion for it; that is why he has a huge impact in Seattle Genetics; with him on the team the company will definitely attain its goals.